Plain-English translation of NCT07257809 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called herombopag can help breast cancer patients who experience dangerously low platelet counts during their standard chemotherapy treatment with T-DM1. Platelets are blood cells that help with clotting, and some patients' platelet counts drop too low during this chemotherapy, which can be serious and stop treatment. The medication aims to keep platelet counts at safe levels so patients can continue their cancer treatment without interruption.
Some breast cancer patients cannot continue their standard chemotherapy because the drug causes their platelet counts to drop to unsafe levels. This trial is testing whether this medication can safely prevent that problem, allowing patients to complete their full course of cancer treatment.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you would take the medication by mouth once daily for 14 days, then continue with your standard T-DM1 chemotherapy treatment. You would need to commit to at least two more cycles of chemotherapy while in the study, with regular blood tests to monitor your platelet counts and check for any side effects. The trial will track whether the medication successfully prevents your platelet counts from dropping too low, allowing you to complete your cancer treatment on schedule.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Enrollment target
~56 participants
Started
October 2025
Primary completion
September 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Tao Qin, MD
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.